Navigation Links
Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
Date:4/15/2011

PITTSBURGH, April 15, 2011 /PRNewswire/ -- Carmell Therapeutics, a company that manufactures novel blood plasma-based biomaterials that accelerate the repair of injured tissues, has closed on a Series A financing it will use to establish a pilot manufacturing facility and collect data for early clinical validation for the Company's first products.

The round was led by Harbor Light Capital Partners, a private investment firm that invests in early and growth stage companies located in the United States. Additional investors in the financing include; Newlin Investment Company, the PLSG Accelerator Fund, LLC, Innovation Works, Ariel Savannah Angels, Blue Tree Allied Angels as well as individual investors.

"This financing establishes a national investor base to support the important work we are doing to develop products to treat injuries to joints and connective tissues," said Carmell Therapeutics President and CEO Alan West. "We're pleased to welcome Harbor Light Capital Partners, Newlin Investment Company, Ariel Savannah Angels, Blue Tree Allied Angels and several western Pennsylvania investment leaders in supporting Carmell and the development of our exciting new products made from blood plasma (Platelet Rich Plasma)."

Platelet-rich plasma (PRP) is receiving widespread clinical use to augment the healing of soft & hard tissue injuries because of the concentration of natural growth factors that occur in platelets.  Carmell's novel materials incorporate both platelet and plasma-derived regenerative factors and are sterile, ready-to-use, easy to handle, shape and suture and exhibit mechanical properties designed to match the repaired tissue.  Carmell's first products include a surgical scaffold for tendon repair and a bone putty form of these plasma-based biomaterials.  Both products address the compelling clinical need for an effective and inexpensive product that accelerates healing.

"Newlin Investment Company believ
'/>"/>

SOURCE Carmell Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... NEW DELHI, India, July 17 Following ... the stock market, Daiichi Sankyo,Company, Limited (TSE: ... Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between Daiichi ... largest,controlling shareholders of Ranbaxy, is binding and ...
... the efforts of two kinds of bacteria to produce hydrogen ... for the other. According to an article in the August ... added bonus: leftover enzymes can be used to scavenge precious ... that convert hydrogen into energy. , Hydrogen has three times ...
... July 16 US Oncology Holdings, Inc. and ... second quarter,financial results on Thursday, August 7, 2008., ... been scheduled at 11:00,a.m., EDT, for the company,s ... this call, representatives of US Oncology,s management,team will ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2Fuel from food waste: bacteria provide power 2
(Date:7/9/2014)... puzzle behind nature,s ability to split the water ... development of artificial photosynthesis for clean, green and ... collaboration of scientists led by researchers with the ... SLAC National Accelerator Laboratory. , Working at ... most powerful x-ray laser, the researchers were able ...
(Date:7/9/2014)... increasing concern about the prevalence of antibiotic-resistant illness, ... new pathway to disabling disease: blocking bacteria,s access ... showed how bacterial siderophore, a small molecule, captures ... bacterial growth as well as how the ... process. Their findings appear in a recent edition ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... WEST LAFAYETTE, Ind. - A Purdue University scientist has found ... unfavorable conditions, a finding he believes could one day be ... environments. David Salt, a professor of horticulture, noticed several ... thaliana that could tolerate higher levels of sodium had come ...
... 31, 2011A compact, self-contained, automated system for surveillance and ... deadly infectious diseases is a step closer to reality, ... the University of California Los Angeles School of Public ... from LANL and the UCLA School of Public Health ...
... and Torosaurus have long been considered the ... the giants, family tree further back in time, when a ... more well-known descendants, making it the earliest known member of ... after the Greek myth of the Titans, rivaled ...
Cached Biology News:Plants can adapt genetically to survive harsh environments 2LANL to certify automated influenza surveillance system 2LANL to certify automated influenza surveillance system 3Newly discovered dinosaur likely father of Triceratops 2
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Biology Products: